Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – menin inhibitors face off again
Kura will see more combo data, while a new contender from Sumitomo emerges.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
Kura leaves some combo questions unanswered
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
